drugset
drugset / Trial / NCT00095537

BMS-599626 in Patients With Advanced Solid Malignancies

NCT00095537 ↗

Phase 1 Completed 60 enrolled Bristol-Myers Squibb
RandomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this trial is to identify the highest oral dose of BMS-599626, a drug that is directed against EGFR and HER2 proteins, that can be given safely on a daily schedule of 21 days with a 7 day rest period in patients with cancer who no longer benefit from other commonly used treatments. The study will also test for other proteins that may be affected by BMS-599626; and the level of study drug in the blood will be studied.

Timeline

Start
2004-03
Primary completion
2006-05
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject panHer Unknown 40 mg Oral
Subject panHer Unknown 60 mg Oral
Subject panHer Unknown 100 mg Oral
Subject panHer Unknown 200 mg Oral
Subject panHer Unknown 320 mg Oral
Subject panHer Unknown 480 mg Oral
Subject panHer Unknown 660 mg Oral
Subject panHer Unknown 880 mg Oral

Indications

cancer metastatic neoplasm